The potential for cross-talk between the parent gene and the pseudogene (MYLK and MYLKP1) and nmMLCK's potential as a cancer biomarker provide unique targets for cancer therapeutics that have the potential to affect cancer cell proliferation. The gene discussed is MYLKP1; the disease is cancer.